Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPTIVATE: Adaptive Platform Trial in Chronic Kidney Disease
NCT06058585Phase 3Recruiting
- Sponsor
- The George Institute for Global Health
- Start
- Sep 2024
- Primary completion
- Dec 2029
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of finerenone and semaglutide in chronic kidney disease (CKD) (4 arms), sponsored by The George Institute for Global Health. Primary endpoints: Core Primary Outcome Measure at 108 weeks, MRA Domain Primary Outcome Measure at 108 weeks and 1 more. Started Sep 2024; status: recruiting.
02
Drugs
finerenonesemaglutide
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT06058585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06058585.